| Praluent (alirocumab) / Sanofi, Regeneron |
NCT01288469: Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia |
|
|
| Completed | 2 | 92 | US | Alirocumab, SAR236553, REGN727, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin) | Sanofi, Regeneron Pharmaceuticals | Hypercholesterolemia | 09/11 | 09/11 | | |
|
|
|
|
NCT01266876: Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia |
|
|
| Completed | 2 | 77 | US, Canada | Alirocumab, REGN727/SAR236553, Placebo | Regeneron Pharmaceuticals, Sanofi | Hypercholesterolemia | 11/11 | 11/11 | | |
|
|
|
NCT01288443: Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy |
|
|
| Completed | 2 | 183 | US | Alirocumab, SAR236553, REGN727, Placebo (for alirocumab), Atorvastatin | Sanofi, Regeneron Pharmaceuticals | Hypercholesterolemia | 12/11 | 12/11 | | |
|
|
|
|
|
NCT01812707: Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan |
|
|
| Completed | 2 | 100 | Japan | Alirocumab, SAR236553, RGEN727, Placebo (for alirocumab), Atorvastatin | Sanofi, Regeneron Pharmaceuticals | Hypercholesterolemia | 01/14 | 01/14 | | |
|
|
|
